CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy

NCT06135909 | Recruiting

• 1 other identifier: CHASE
• Study Type: observational
• Target: 5,000
• Locations: 1 country
• Sites: 1

Brief Summary

CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)

Conditions

Pulmonary Hypertension

Outcome Measures

Primary Outcomes (1)

• Incidence of clinical worsening events 1 year after enrollment

  All-cause death, Pulmonary hypertension progression associated with re-hospitalization, Progress of pulmonary hypertension disease

  1 year after enrollment

Secondary Outcomes (1)

• Incidence of all-cause death 1,3,5 year(s) after enrollment

  1,3,5 year(s) after enrollment

Study Arms (1)

PH Patients receiving targeted drugs treatment

Patients with pulmonary hypertension receiving targeted drugs treatment

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with pulmonary hypertension receiving targeted therapy

You may qualify if:

• Sign informed consent;
• Between the ages of 18 and 85;
• Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).

You may not qualify if:

• Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;
• Patients with malignant tumor and other diseases and life expectancy of less than half a year;
• Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension

Sponsors & Collaborators

• Chinese Pulmonary Vascular Disease Research Group: lead

Study Sites (1)

Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMC

Beijing, 100037, China

RECRUITING

MeSH Terms

Conditions

Hypertension, Pulmonary

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Hypertension; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Zhihong Liu, M.D., Ph.D

  Chinese Academy of Medical Sciences, Fuwai Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhihong Liu, M.D., Ph.D

CONTACT

8601088396816; zhihongliufuwai@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 12, 2023
• First Posted: November 18, 2023
• Study Start: January 1, 2020
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: January 18, 2024

Record last verified: 2023-11

Locations

CN (1)